Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Psoriasis and Pruritus Trial of SNA-120

Trial Profile

A Phase III Psoriasis and Pruritus Trial of SNA-120

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2019

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Pruritus; Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 14 Mar 2019 According to a Sienna Biopharmaceuticals media release, following an end-of-phase 2 (EOP2) meeting with FDA the company plans to initiate this trial is expected to commence in the second half of 2019.
    • 03 Dec 2018 According to a Sienna Biopharmaceuticals media release, the company expect to start this phase 3 study for psoriasis in the second half of 2019.
    • 20 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top